Top

Published in:

01-12-2009 | Letter to the editor

Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer

Authors: Najim Ameziane, Ans M. W. van den Ouweland, Muriel A. Adank, Raymond N. C. P. Vijzelaar, Abdellatif Errami, Josephine C. Dorsman, Hans Joenje, Hanne Meijers-Heijboer, Quinten Waisfisz

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Excerpt

Breast cancer (BC) is the most common malignancy in women worldwide. It is estimated that 5–10% of all BC cases may be caused by germline mutations in breast cancer susceptibility genes [19, 21]. BRCA1 and BRCA2 are the major known BC susceptibility genes accounting for ~16% of the familial BC cases [2]. Other BC susceptibility genes include TP53 [16], PTEN [15], ATM [24], LKB1/STK11 [8], CHEK2 [28], BRIP1/FANCJ [27], and PALB2/FANCN [22]. However to date, the majority of familial BC cases can not be attributed to mutations in one of the known susceptibility genes. …

Alter BP (2003) Cancer in Fanconi anemia, 1927–2001. Cancer 97:425–440. doi:10.1002/cncr.11046 CrossRefPubMed

Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 83:1301–1308. doi:10.1054/bjoc.2000.1407 CrossRef

Bridge WL, Vandenberg CJ, Franklin RJ et al (2005) The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat Genet 37:953–957. doi:10.1038/ng1627 CrossRefPubMed

Cao AY, Huang J, Hu Z et al (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114:457–462. doi:10.1007/s10549-008-0036-z CrossRefPubMed

Erkko H, Xia B, Nikkila J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446:316–319. doi:10.1038/nature05609 CrossRefPubMed

Foulkes WD, Ghadirian P, Akbari MR et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9:R83. doi:10.1186/bcr1828 CrossRefPubMed

Garcia MJ, Fernandez V, Osorio A et al (2008) Analysis of FANCB and FANCN/PALB2 Fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 113:545–551. doi:10.1007/s10549-008-9945-0 CrossRefPubMed

Giardiello FM, Brensinger JD, Tersmette AC et al (2000) Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology 119:1447–1453. doi:10.1053/gast.2000.20228 CrossRefPubMed

Gunnarsson H, Arason A, Gillanders EM et al (2008) Evidence against PALB2 involvement in Icelandic breast cancer susceptibility. J Negat Results Biomed 7:5. doi:10.1186/1477-5751-7-5 CrossRefPubMed

10.

Houghtaling S, Timmers C, Noll M et al (2003) Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 17:2021–2035. doi:10.1101/gad.1103403 CrossRefPubMed

11.

Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609. doi:10.1126/science.1073834 CrossRefPubMed

12.

Levitus M, Waisfisz Q, Godthelp BC et al (2005) The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 37:934–935. doi:10.1038/ng1625 CrossRefPubMed

13.

Levran O, Attwooll C, Henry RT et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37:931–933. doi:10.1038/ng1624 CrossRefPubMed

14.

Lewis AG, Flanagan J, Marsh A et al (2005) Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res 7:R1005–R1016. doi:10.1186/bcr1336 CrossRefPubMed

15.

Lynch ED, Ostermeyer EA, Lee MK et al (1997) Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61:1254–1260. doi:10.1086/301639 CrossRefPubMed

16.

Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238. doi:10.1126/science.1978757 CrossRefPubMed

17.

Mathew CG (2006) Fanconi anaemia genes and susceptibility to cancer. Oncogene 25:5875–5884. doi:10.1038/sj.onc.1209878 CrossRefPubMed

18.

Meijer GA (2007) The 13th Fanconi anemia gene identified: FANCI—importance of the ‘Fanconi anemia pathway’ for cellular oncology. Cell Oncol 29:181–182PubMed

19.

Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ et al (2007) Genetic susceptibility for breast cancer: how many more genes to be found? Crit Rev Oncol Hematol 63:125–149. doi:10.1016/j.critrevonc.2006.12.004 CrossRefPubMed

20.

Pylkas K, Erkko H, Nikkila J et al (2008) Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 8:146. doi:10.1186/1471-2407-8-146 CrossRefPubMed

21.

Rahman N, Scott RH (2007) Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 16:60–66 Spec No 1:CrossRef

22.

Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39:165–167. doi:10.1038/ng1959 CrossRefPubMed

23.

Reid S, Schindler D, Hanenberg H et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162–164. doi:10.1038/ng1947 CrossRefPubMed

24.

Renwick AD, Thompson S, Seal P et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38:873–875. doi:10.1038/ng1837 CrossRefPubMed

25.

Schouten JP, McElgunn CJ, Waaijer R et al (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57. doi:10.1093/nar/gnf056 CrossRefPubMed

26.

Seal S, Barfoot R, Jayatilake H et al (2003) Evaluation of Fanconi anemia genes in familial breast cancer predisposition. Cancer Res 63:8596–8599PubMed

27.

Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38:1239–1241. doi:10.1038/ng1902 CrossRefPubMed

28.

The CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10, 860 breast cancer cases and 9, 065 controls from 10 studies. Am J Hum Genet 74:1175–1182. doi:10.1086/421251 CrossRef

29.

Tischkowitz M, Sabbaghian N, Ray AM et al (2008) Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate 68:675–678. doi:10.1002/pros.20729 CrossRefPubMed

30.

Van der Hout AH, van den Ouweland AM, van der Luijt RB et al (2006) A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat 27:654–666. doi:10.1002/humu.20340 CrossRefPubMed

31.

Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8:735–748. doi:10.1038/nrg2159 CrossRefPubMed

32.

Xia B, Dorsman JC, Ameziane N et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161. doi:10.1038/ng1942 CrossRefPubMed

Title: Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer
Authors: Najim Ameziane
Ans M. W. van den Ouweland
Muriel A. Adank
Raymond N. C. P. Vijzelaar
Abdellatif Errami
Josephine C. Dorsman
Hans Joenje
Hanne Meijers-Heijboer
Quinten Waisfisz
Publication date: 01-12-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0428-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2009

A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines

Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care

Reporting of race and ethnicity in breast cancer research: room for improvement

Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study

Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERα

No evidence of familial correlation in breast cancer metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer